Li et al. [5] postulated that because vimentin has a twofold role in the disease, both in the viral infection and in the associated life-threatening lung inflammation, the use of vimentin-targeted drugs may offer a synergistic advantage as compared with other treatments not targeting vimentin, and those drugs tested in clinical trials may broaden the therapeutic options against SARS-CoV-2. The gene discussed is VIM; the disease is inflammatory response.